Stockscreener 앱 받기
3.56
1.14%
0.04
시간 외 거래:
3.64
0.08
+2.25%
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Are medical stocks lagging C4 Therapeutics (CCCC) this year? - MSN
Clinical trial participation drives development of innovative treatments, C4 Therapeutics, Inc. - Traders Union
C4 Therapeutics to Participate in Upcoming Conferences - Investing News Network
C4 Therapeutics to speak at TD Cowen, Jefferies, Goldman healthcare events - Stock Titan
C4 Therapeutics deepens Roche alliance to target breakthrough cancer therapies - MSN
C4 Therapeutics (NASDAQ: CCCC) — Squadron Fund reports 5.55M shares - Stock Titan
Biotech C4 Therapeutics gives new hire options on 85,480 shares - Stock Titan
C4 Therapeutics, Inc. to present new cemsidomide Phase 1 data at EHA Hematology 2026 Congress - Traders Union
C4 Therapeutics Realigns Finance Leadership After Officer Departure - The Globe and Mail
Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Point72 reports 169,096-share stake in C4 Therapeutics (CCCC) as of Mar 31, 2026 - Stock Titan
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics (NASDAQ: CCCC) names CFO as principal accountant - Stock Titan
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance
C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets - simplywall.st
C4 Therapeutics (CCCC) — Sirenia/Silverstein report 23.5M shares, near 10% stake - Stock Titan
C4 Therapeutics, Inc.Common Stock (NQ: CCCC - FinancialContent
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Bicara Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics (CCCC) Q1 Loss Of US$25.1 Million Reinforces Profitability Concerns - Sahm
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2026 - BioSpace
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biogen Inc. stock (US09062X1037): Q1 milestone payment amid partner C4 Therapeutics earnings - AD HOC NEWS
C4 Therapeutics (CCCC) Reports Strong Q1 Revenue and Clinical Ad - GuruFocus
C4 Therapeutics, Inc. (CCCC) reports Q1 loss, lags revenue estimates - MSN
CCCC Financials: Income Statement, Balance Sheet & Cash Flow | C4 Therapeutics, Inc. - Stock Titan
C4 Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights - Investing News Network
C4 Therapeutics Reports Q1 Results and Clinical Advancements - TipRanks
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
C4 Therapeutics Advances Cemsidomide for Multiple Myeloma Treatment Amid Ongoing Clinical Trials and Expanded Partnership with Roche - Quiver Quantitative
C4 Therapeutics 1Q 2026: Revenue $6.15M, EPS ($0.2) — 10-Q Summary - TradingView
C4 Therapeutics (NASDAQ: CCCC) Q1 loss, $268M cash and new Roche DAC deal - Stock Titan
C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
C4 Therapeutics (NASDAQ: CCCC) Q1 loss $25.1M with $268M cash runway to 2028 - Stock Titan
Biotech behind new myeloma drug teams with Roche, holds cash to 2028 - Stock Titan
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new Fulcrum hires get 55,500 stock options at $7.02 a share - Stock Titan
Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
CCCC Stock Price, Quote & Chart | C4 THERAPEUTICS INC (NASDAQ:CCCC) - ChartMill
Mineralys Therapeutics reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Two new Mineralys hires get stock options and RSUs under Nasdaq rule - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
2.98%
1.33%
자본화:
|
볼륨(24시간):